Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Withdrawn 3Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Other 4Lymphoid 2Sarcoma 1Plasma cell 1Other solid neoplasm 1Myeloid 1Gynecologic 1Classical hematology 1

Conditions

Mucositis 4Hematologic Neoplasms 3Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Graft vs Host Disease 1

Interventions

Exercise 27Metformin 24Methods 14Radiotherapy 13Early Intervention, Educational 13Educational Status 12Counseling 12Surveys and Questionnaires 10Standard of Care 10Nutrition Assessment 9Resistance Training 8Diet Therapy 8Cisplatin 8naloxegol 7Tirzepatide 7Diet 7alvimopan 6Psychiatric Rehabilitation 6Fibroblast Growth Factor 7 6Caloric Restriction 6Radiation 5Low-Level Light Therapy 5Liraglutide 5Injections 5Exenatide 5Dexamethasone 5Cryotherapy 5semaglutide 4angiotensin I (1-7) 4Vitamin D 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × angiotensin I (1-7) × Other × Clear all
NCT01300611 2020-12-08

USBTXA127CBT

Tarix Pharmaceuticals

Phase 1 Terminated
20 enrolled
LymphoidMyeloidOtherOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Mucositis, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT01554254 2016-08-31

Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation

Tarix Pharmaceuticals

Phase 2 Withdrawn
OtherOther hematologic neoplasm

Hematologic Neoplasms, Mucositis

NCT01882374 2016-08-31

Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation

Tarix Pharmaceuticals

Phase 2 Withdrawn
OtherOther hematologic neoplasm

Hematologic Neoplasms, Mucositis

NCT01882387 2016-08-31

Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

Tarix Pharmaceuticals

Phase 2 Withdrawn
OtherOther hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡